Bispezifische Antikörper gegen CEACAM5 und CD47

Details

Veröffentlichungs-Nr.

EP3831849

Aktenzeichen

EP19213002

Anmeldetag

2. Dezember 2019

Veröffentlichung

9. Juni 2021

Rechtsraum

EP

IPC

C07K16/28C07K16/30

Abstract

The present invention relates to bispecific antibodies which bind to human carcinoembryonic antigen CEACAM5 and human CD47. In addition, the present invention relates to polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further relates to methods for selecting and producing such antibodies and to methods of using such antibodies in the treatment of diseases. The invention also relates to the therapeutic use of the bispecific antibodies in monotherapy and in combination therapy.

Anmelder

Firma

LamKap Bio beta AG

Land

🇨🇭 Schweiz

Fachgebiete